PDX Core

PDX核心摘要 患者衍生异种移植物（PDX）核心是华盛顿大学PDX开发的中心 试验中心（WU-PDTC）。它将负责开发、组织、表征、存储和 传播高质量的无病原体PDX模型，用于研究抗癌药物的研究项目， 在WU-PDTC内外。利用先前的成功经验和精简高效的基础架构，PDX 核心将继续PDX的发展，重点是创造高价值的标本，从生物学 优先处理的标本（例如，治疗抵抗性病例）。人类和小鼠肿瘤的关联评价 临床和转化研究所（ICTS）和实体瘤组织库的（哈姆雷特）PDX核心 和登记处（STTBR）分别由李博士和菲尔兹博士领导，在产生 来自各种癌症的PDX模型，并利用这些模型进行药物测试。这些协同 项目已经从>15种实体瘤中生成了> 1，000个模型，包括大量的恶性肿瘤病例 (e.g.治疗抗性胰腺癌和三阴性乳腺癌）和基因组相似（例如HER-2 扩增的）实体瘤，导致了ETCTN的多项临床试验。这些现有的模型将成为 更新WU-PDTC的一部分，其中约400个新的PDX模型将被开发并添加到该系列中。的 新的PDX模型将进一步增强我们支持正在进行的项目的能力，并为以下方面提供新的机会： 临床优先癌症主题的研究。利用其强大的蛋白质组学能力， 建议的WU-PDTC和WUSM，我们将扩展这些PDX模型的特征，包括切割- 边缘基因组学、转录组学、蛋白质组学和代谢组学。这将为调查人员提供更多的 突变谱、分子特征、克隆结构和异质性的综合图 帮助癌症亚型和靶点选择。除了WU-PDTC的研究项目外，PDX PDX核心集合中的模型也将与其他PDTC共享，并广泛提供给 授权的非网络调查员。现有的基础设施与大型临床肿瘤学项目相结合， 世界大学和特别强有力的机构支持，包括配套资金，将确保世界大学的目标- PDTC PDX核心目标是可以实现的。

PDX CORE SUMMARY The Patient Derived Xenograft (PDX) Core is the epicenter of the Washington University PDX Development and Trial Center (WU-PDTC). It will be responsible for the development, organization, characterization, storage, and dissemination of high quality pathogen free PDX models for research projects investigating anticancer agents, within and outside of WU-PDTC. Leveraging prior success and streamlined and efficient infrastructure, the PDX Core will continue PDX development with a focus on creation of high-value specimens from biologically prioritized specimens (e.g. treatment resistant cases). The Human and Mouse Linked Evaluation of Tumors (HAMLET) PDX Core at the Institute of Clinical and Translational Study (ICTS) and the Solid Tumor Tissue Bank and Registry (STTBR) led by Drs. Li and Fields, respectively, have a proven record of success in generating PDX models from a wide variety of cancers and in utilizing these models for drug testing. These synergistic programs have generated >1,000 models from >15 solid tumors, including large cohorts of recalcitrant cases (e.g. treatment resistant pancrcreatic and triple-negative breast cancer) and genomically similar (e.g. HER-2 amplified) solid tumors that have led to multiple clinical trials in the ETCTN. These existing models will become part of the renewal WU-PDTC, where ~400 new PDX models will be developed and added to this collection. The new PDX models will further enhance our capability to support ongoing projects and open new opportunities for research in clinically prioritized cancer themes. Taking advantage of the strong proteogenomic capability within the proposed WU-PDTC and WUSM, we will expand the characterization of these PDX models to include cutting- edge genomics, transcriptomics, proteomics, and metabolomics. This will provide investigators with a more comprehensive picture of the mutational profiles, the molecular signatures, clonal structures, and heterogeneities of the models to help with cancer sub-typing and target selection. Besides research projects at WU-PDTC, PDX models in the PDX Core collection will also be shared with other PDTCs and made broadly available to authorized non-network investigators. Existing infrastructure copuled with the large clinical oncology program at WU and exceptionally strong institutional support, including matching funds, will ensure that the goals of the WU- PDTC PDX Core goals are achievable.